Stonebridge Capital Management Inc. increased its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 3.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,704 shares of the pharmaceutical company’s stock after purchasing an additional 400 shares during the period. Stonebridge Capital Management Inc.’s holdings in GlaxoSmithKline were worth $382,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Concord Wealth Partners acquired a new stake in GlaxoSmithKline during the 4th quarter worth $29,000. Kathmere Capital Management LLC acquired a new stake in GlaxoSmithKline during the 4th quarter worth $29,000. ADE LLC acquired a new stake in GlaxoSmithKline during the 4th quarter worth $30,000. Key Financial Inc acquired a new stake in GlaxoSmithKline during the 4th quarter worth $31,000. Finally, BNC Wealth Management LLC acquired a new stake in GlaxoSmithKline during the 3rd quarter worth $34,000. Hedge funds and other institutional investors own 11.83% of the company’s stock.
Shares of GSK traded up $0.51 during mid-day trading on Thursday, hitting $36.57. The company had a trading volume of 181,415 shares, compared to its average volume of 5,990,228. The business’s 50-day simple moving average is $35.42 and its 200-day simple moving average is $36.60. The company has a quick ratio of 0.61, a current ratio of 0.90 and a debt-to-equity ratio of 1.13. GlaxoSmithKline plc has a 1-year low of $33.26 and a 1-year high of $43.18. The stock has a market cap of $98.47 billion, a PE ratio of 11.20, a P/E/G ratio of 2.93 and a beta of 0.67.
GlaxoSmithKline (NYSE:GSK) last released its earnings results on Tuesday, February 2nd. The pharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.64 by ($0.02). GlaxoSmithKline had a return on equity of 29.60% and a net margin of 18.50%. The company had revenue of $8.74 billion during the quarter, compared to analyst estimates of $8.71 billion. During the same period in the prior year, the business posted $0.39 earnings per share. GlaxoSmithKline’s revenue was down 1.8% on a year-over-year basis. On average, sell-side analysts expect that GlaxoSmithKline plc will post 3.07 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 8th. Investors of record on Friday, February 19th will be issued a $0.628 dividend. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date is Thursday, February 18th. This represents a $2.51 annualized dividend and a yield of 6.87%. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 78.23%.
GSK has been the subject of a number of analyst reports. DZ Bank restated a “buy” rating on shares of GlaxoSmithKline in a research report on Wednesday, December 16th. Berenberg Bank restated a “buy” rating on shares of GlaxoSmithKline in a research report on Thursday, February 11th. UBS Group restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, February 8th. Morgan Stanley restated an “equal weight” rating on shares of GlaxoSmithKline in a research report on Friday, February 12th. Finally, Credit Suisse Group downgraded shares of GlaxoSmithKline from a “neutral” rating to an “underperform” rating in a research report on Wednesday, January 20th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company’s stock. GlaxoSmithKline has an average rating of “Hold” and a consensus price target of $41.00.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).